Elicio Therapeutics Inc (ELTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.40-10.26%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ELTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company expects that its current cash and cash equivalents will support operations into the first quarter of 2027.
Stated in 2 of 2 supplied quarters. Management reported: “Net loss for the second quarter of 2026 was $8.2 million, compared to $10.6 million for the second quarter of 2025.” “Cash and cash equivalents were $23.5 million as of June 30, 2026.” Net income was $-8.217 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company expects that its current cash and cash equivalents will support operations into the first quarter of 2027.”
“The Company expects its current cash and cash equivalents to support planned operations into Q4 2026, beyond the anticipated AMPLIFY-7P Phase 2 event-driven DFS analysis expected mid-year 2026.”
The trial did not meet the primary endpoint but Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-…
Stated in 2 of 2 supplied quarters. Management reported: “The trial did not meet the primary endpoint but Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002 7P in adjuvant PDAC.” “Post-hoc analyses showed significant DFS improvement (R0: HR 0.65, p=0.048, n=121) in lower residual disease patients.”
“The trial did not meet the primary endpoint but Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-…”
““We remain focused on advancing the Phase 2 AMPLIFY-7P trial and anticipate reaching the event-driven primary DFS analysis of ELI-002 7P in post-resection KRAS-driven PDAC mid- year 2026,” said Rober…”
“Our recent financing provided us with the capital needed to evaluate initial data from our planned Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor with or without an anti…
Stated in 1 of 2 supplied quarters. Management reported: ““Our recent financing provided us with the capital needed to evaluate initial data from our planned Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor, which is anticipated to begin in the fourth quarter of this year.” “Recent Highlights • Reported multiple complete responses following ELI-002 7P treatment and subsequent checkpoint inhibition in metastatic mKRAS pancreatic cancer, which Elicio believes supports the planned Phase 1 combination study.”
““Our recent financing provided us with the capital needed to evaluate initial data from our planned Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor with or without an anti…”
Continue evaluation of Phase 2 AMPLIFY-7P trial data, including subgroup analyses, and refine Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic cancer.
Pursue financing and partnerships to support Phase 3 development and broader pipeline advancement.
Over the trailing year it converted 1.00x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.